LAS VEGAS, Aug. 19, 2020 /PRNewswire/ -- JanOne Inc.
(Nasdaq: JAN), a company focused on developing treatments to market
for conditions that cause severe pain and drugs with non-addictive,
pain-relieving properties, today announced that it will
be presenting at the 12th Annual LD 500 Conference on
Thursday, September 3, 2020 at
3:00 PM ET. Tony Giordano, PhD, Chief Scientific Officer of
JanOne, will present virtually to an online audience.
JanOne recently entered into an agreement with CATO SMS, a
world-leading, international regulatory and clinical contract
research organization, to assist JanOne in expanding its current
FDA authorized Investigational New Drug (IND) for JAN101, an oral,
sustained release formulation of sodium nitrite, to treat vascular
complications to potentially restore endothelial cell function in
COVID-19 patients. JAN101 is expected to enter
Phase 2b trials in early 2021 to treat Peripheral Artery
Disease (PAD). The company recently filed an investor deck
and scientific deck. Please use the links below to view the
Registration and webcast information:
"We have been waiting for the 2020 LD 500 Virtual Conference all
year long. Due to Covid-19, for the first time, LD Micro is
accessible to everyone, and we are honored to welcome you to one of
the most trusted platforms in the microcap space," stated
Chris Lahiji, Founder of LD.
The LD 500 will take place on September
1st through the 4th.
View JanOne's profile
Forward-Looking and Cautionary Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. In accordance with the safe harbor provisions of this Act,
statements contained herein that look forward in time that include
everything other than historical information, including statements
relating to (i) JAN101's expectation of when it will enter Phase
2b trials to treat PAD, (ii) whether
JAN101 can treat vascular complications in COVID-19 patients, and
(iii) the timing of the submission by the company of the IND
package for the FDA. These forward-looking statements can be
identified by terminology such as "will," "aims," "expects,"
"anticipates," "future," "intends," "plans," "believes,"
"estimates" and similar statements. JanOne may also make written or
oral forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission (the "SEC") on Forms 10-K and
10-Q, Current Reports on Form 8-K, in its annual report to
stockholders, in press releases, and other written materials and in
oral statements made by its officers, directors or employees to
third parties. There can be no assurance that such statements will
prove to be accurate and there are a number of important factors
that could cause actual results to differ materially from those
expressed in any forward-looking statements made by the company,
including, but not limited to, plans and objectives of management
for future operations or products, the market acceptance or future
success of our products, and our future financial performance. The
company cautions that these forward-looking statements are further
qualified by other factors including, but not limited to, those set
forth in the company's Annual Report on Form 10-K for the fiscal
year ended December 28, 2019
(available at http://www.sec.gov). JanOne undertakes no obligation
to publicly update or revise any statements in this release,
whether as a result of new information, future events, or
JanOne (NASDAQ: JAN) is focused on developing medications to
market to treat diseases that cause severe pain. By alleviating
pain at the source, JanOne aims to reduce the need for opioid
prescriptions to treat disease associated pain that can lead to
opioid abuse. The company is also exploring solutions for
non-addictive pain medications. Its lead candidate JAN101 is for
treating peripheral artery disease (PAD), a condition that affects
over 8.5 million Americans. JAN101 demonstrated positive results in
a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021.
JanOne is dedicated to funding resources toward innovation,
technology, and education for PAD, associated vascular conditions
and neuropathic pain. JanOne continues to operate its legacy
businesses under their current brand names, ARCA Recycling and
GeoTraq, both of which are undergoing review to determine
appropriate strategic alternatives. For more information,
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an
independent resource to the microcap world.
What started as a newsletter highlighting unique companies, has
transformed into the pre-eminent event platform in the space.
The upcoming "500" in September is the Company's most ambitious
project yet, and the first event that is accessible to
For those interested in attending, please contact David Scher at firstname.lastname@example.org or visit
www.ldmicro.com for more information.
Investor Relations & Media Contact
1 (800) 400-2247
View original content to download